Rationale and Role of High Loading Dose Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention - Pharmacology & Pharmacy

PP > Vol.3 No.4, October 2012

Volume 3, Issue 4 (October 2012)

ISSN Print: 2157-9423 ISSN Online: 2157-9431

Google-based Impact Factor: 0.70 Citations h5-index & Ranking

Rationale and Role of High Loading Dose Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention ()

HTML

Download as PDF (Size: 73KB) PP. 481-484

DOI: 10.4236/pp.2012.34066 5,173 Downloads 8,330 Views Citations

Author(s)

Sam T. Mathew, Gayathri Devi S, Prasanth V. V, Vinod B

Affiliation(s)

Accenture Pharmaceutical Services, Bangalore, India.
Department of Pharmaceutical Chemistry, Pushpagiri College of Pharmacy, Thiruvalla, Kerala, India.
Department of Pharmaceutics Sikkim Manipal University, Bangalore, India.
Department of Pharmaceutics, Gautham College of Pharmacy, Bangalore, India.

ABSTRACT

Antiplatelet therapy, which reduces platelet activation and aggregation, is the corner stone of treatment for patients undergoing percutaneous coronary intervention (PCI). Clopidogrel is an established oral antiplatelet medication of thienopyridine class, which inhibits blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. Many studies have revealed that high loading dose clopidogrel in patients undergoing PCI. This review article investigates the rationale and role of high loading dose clopidogrel in patients undergoing PCI.

KEYWORDS

Clopidogrel; Antiplatelet Therapy; Percutaneous Coronary Intervention

Share and Cite:

S. Mathew, G. S, P. V and V. B, "Rationale and Role of High Loading Dose Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention," Pharmacology & Pharmacy, Vol. 3 No. 4, 2012, pp. 481-484. doi: 10.4236/pp.2012.34066.

Cited by